Pfizer Inc. (NYSE:PFE) Shareholders Set to Receive $0.43 Quarterly Dividend

Key Points

• Pfizer declared a quarterly dividend of $0.43 per share, payable December 7 to shareholders of record on November 6. The dividend represents $1.72 annually and a 6.3% yield.
• Pfizer has raised its dividend for 16 consecutive years, and its 55.8% payout ratio indicates the dividend is currently covered by earnings. Analysts expect a future payout ratio of approximately 58.3%.
• In its latest quarter, Pfizer reported EPS of $0.77 and revenue of $15.03 billion, beating analyst estimates of $0.68 EPS and $14.40 billion in revenue.

Pfizer Inc. (NYSE:PFE - Get Free Report) declared a quarterly dividend on Tuesday, October 6th. Stockholders of record on Friday, November 6th will be paid a dividend of $0.43 per share by the biopharmaceutical company on Monday, December 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.3%. The ex-dividend date of this dividend is Friday, November 6th.

Pfizer has decreased its dividend payment by an average of 0.1%annually over the last three years and has increased its dividend every year for the last 16 years. Pfizer has a payout ratio of 55.8% meaning its dividend is sufficiently covered by earnings. Research analysts expect Pfizer to earn $2.95 per share next year, which means the company should continue to be able to cover its $1.72 annual dividend with an expected future payout ratio of 58.3%.

Pfizer Stock Performance

Shares of PFE stock opened at $27.48 on Wednesday. The company has a market capitalization of $156.63 billion, a price-to-earnings ratio of 36.16, a P/E/G ratio of 1.84 and a beta of 0.32. Pfizer has a 1-year low of $23.62 and a 1-year high of $29.21. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The stock's fifty day simple moving average is $27.50 and its 200-day simple moving average is $26.48.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the prior year, the business earned $0.78 EPS. The business's revenue for the quarter was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts predict that Pfizer will post 2.98 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pfizer

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Moody National Bank Trust Division lifted its stake in Pfizer by 3.7% in the third quarter. Moody National Bank Trust Division now owns 86,627 shares of the biopharmaceutical company's stock valued at $2,471,000 after acquiring an additional 3,061 shares during the last quarter. Legacy Private Trust Co. acquired a new position in shares of Pfizer during the 3rd quarter worth $207,000. Park National Corp OH raised its holdings in shares of Pfizer by 6.4% during the 3rd quarter. Park National Corp OH now owns 257,556 shares of the biopharmaceutical company's stock valued at $7,345,000 after purchasing an additional 15,475 shares in the last quarter. Baker Tilly Wealth Management LLC lifted its stake in shares of Pfizer by 35.0% in the 3rd quarter. Baker Tilly Wealth Management LLC now owns 12,951 shares of the biopharmaceutical company's stock valued at $369,000 after purchasing an additional 3,361 shares during the last quarter. Finally, Argent Capital Management LLC acquired a new stake in shares of Pfizer in the 3rd quarter valued at $8,128,000. Institutional investors own 68.36% of the company's stock.

About Pfizer

Pfizer Inc NYSE: PFE is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company's portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.